Avita Medical Ltd ((RCEL)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Avita Medical Ltd is conducting a clinical study titled ‘A Prospective Multicenter Single-arm Clinical Study to Investigate Clinical Outcomes When Cohealyx™ is Used for the Management of Full Thickness Wounds Post-surgical Excision.’ The study aims to evaluate the effectiveness of Cohealyx Collagen Matrix in treating full thickness wounds that require skin grafts, focusing on the time taken for wound closure.
The intervention being tested is the Cohealyx device, which is applied post-surgical excision to aid in wound healing. It is designed to support the healing process of full thickness wounds, including burns and trauma wounds.
This is an interventional study with a single-group model, where no masking is used. The primary purpose is treatment, with the study focusing on the application of Cohealyx followed by an autologous split-thickness skin graft.
The study began on January 8, 2025, with the latest update submitted on September 17, 2025. These dates are crucial as they indicate the study’s progression and the timeliness of the data being collected.
The outcome of this study could significantly impact Avita Medical’s stock performance and investor sentiment, as successful results may enhance the company’s market position in wound care. Competitors in the wound management industry will likely monitor these developments closely.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.